Document text
Principal Investigator: Jason J Hassenstab
Organization: WASHINGTON UNIVERSITY
Fiscal Year: 2024
Award: $208,883
Funding agency: National Institute on Aging
PROJECT SUMMARY
The Down Syndrome – Ambulatory Research in Cognition (DS-ARC) study will develop and validate a
smartphone-based digital cognitive assessment designed specifically for participants at risk for Down
syndrome-associated Alzheimer’s disease (DS-AD). We will partner with sites in London, Barcelona, Munich,
and Gothenburg to develop and validate this approach in different cultures and languages. Nearly all
individuals with Down syndrome have elevated levels of Alzheimer’s disease (AD) biomarkers by the time they
are in their 30s or 40s, though not all show symptoms of AD. It is during the pre-symptomatic and early
symptomatic stages of DS-AD that an in-depth understanding of cognitive changes is crucial, as therapeutic
interventions to stop, slow, or prevent disease are focused on these critical periods. Typically, prevention trials
and observational studies in AD populations assess cognition with standard “table top” paper and pencil tests.
But these conventional methods have several drawbacks. First, performance is influenced by day to day
fluctuations in stress, fatigue, sleep patterns, and mood. Second, the testing takes place in environments that
are fundamentally different from where cognition is relied upon to function in daily life. Finally, by design,
cognition is typically assessed in “one-shot” in extended testing sessions on an annual or semiannual basis.
The DS-ARC study will address these difficulties by developing a smartphone-based assessment solution
adapted specifically for individuals with Down syndrome. This approach uses a measurement “burst” design in
which participants complete very brief cognitive tests on their smartphones several times per day for one week
while living in their natural environments. Instead of focusing on one of these measurements, tests are
averaged across the week to provide a score that captures and normalizes natural variability and dramatically
increases reliability. Studies of our original ARC assessments in autosomal dominant and sporadic AD
demonstrate extraordinary reliability and strong relationships with AD biomarkers, while reducing costly and
burdensome in-clinic evaluations. The study has two phases: a 2-year development phase and a 3-year
validation phase. In the development phase, we will adapt an existing smartphone application called the
Ambulatory Research in Cognition (ARC) app for use in DS-AD studies. This will include an iterative pilot
testing process for psychometrics and task development, focus groups and user experience testing to address
accessibility and compatibility concerns for DS-AD populations, and readiness audits to ensure that the DS-
ARC app meets strict compliance guidelines for clinical trial applications. In Phase 2, participants complete DS-
ARC assessments every 6 months and complete standard clinical, cognitive, and blood tests for AD
biomarkers annually. We hypothesize that DS-ARC assessments are accessible, sensitive, and reliable
indicators of cognitive change in DS-AD and will exhibit associations with AD biomarkers and disease stage
over and above those of conventional in-clinic assessments.
Terms: <AD dementia><AD pathology><AD prevention><Address><Adoption><Alzheimer Type Dementia><Alzheimer disease dementia><Alzheimer disease prevention><Alzheimer prevention><Alzheimer risk factor><Alzheimer sclerosis><Alzheimer syndrome><Alzheimer's><Alzheimer's Disease><Alzheimer's biomarker><Alzheimer's blood test><Alzheimer's disease biological marker><Alzheimer's disease blood test><Alzheimer's disease pathology><Alzheimer's disease risk><Alzheimer's pathology><Alzheimers Dementia><Alzheimer’s biological marker><Alzheimer’s disease biomarker><Amyloid><Amyloid Substance><Android App><Android Application><Astroprotein><Biological Markers><Blood><Blood Diseases><Blood Plasma><Blood Reticuloendothelial System><Blood Serum><Cell Phone><Cell Phone Application><Cell phone App><Cellular Phone><Cellular Phone App><Cellular Phone Application><Cellular Telephone><Chromosome 21><Clinic><Clinical><Clinical Trials><Cognition><Cognitive><Cognitive Disturbance><Cognitive Impairment><Cognitive decline><Cognitive function abnormal><Data><Development><Devices><Disease><Disorder><Disturbance in cognition><Down's Syndrome><Environment><Evaluation><Exhibits><Fatigue><Focus Groups><GFA-Protein><GFAP><Gene variant><Geography><Glial Fibrillary Acid Protein><Glial Fibrillary Acidic Protein><Glial Intermediate Filament Protein><Goals><Guidelines><Hematologic Diseases><Hematological Disease><Hematological Disorder><Human Resources><Impaired cognition><Individual><International><Laboratories><Lack of Energy><Langdon Down syndrome><Language><Life><Light><London><Manpower><Measurement><Measures><Methodology><Methods><Mobile Phones><Mongolism><Moods><Nature><Observation research><Observation study><Observational Study><Observational research><Outcome><Paper><Participant><Performance><Persons><Phase><Phenotype><Photoradiation><Plasma><Plasma Serum><Population><Predisposition><Preparedness><Prevention trial><Primary Senile Degenerative Dementia><Process><Psychometrics><Readiness><Research><Reticuloendothelial System, Serum, Plasma><Risk><Role><Series><Serum><Site><Sleep><Smart Phone App><Smart Phone Application><Smartphone App><Source><Stress><Susceptibility><Symptoms><Techniques><Technology><Testing><Therapeutic Intervention><Time><Trisomy 21><Validation><Work><allele variant><allelic variant><alzheimer risk><assess effectiveness><autosomal dominant AD><autosomal dominant Alzheimer's disease><autosome><bio-markers><biologic marker><biomarker><blood disorder><cell phone based app><chromosome 21 trisomy syndrome><cognitive ability><cognitive assessment><cognitive change><cognitive dysfunction><cognitive loss><cognitive testing><cohort><congenital acromicria syndrome><cost><critical period><design><designing><determine effectiveness><developmental><digital><digital assessment><disease phenotype><effectiveness assessment><effectiveness evaluation><evaluate effectiveness><examine effectiveness><experience><genetic variant><genomic variant><handheld mobile device><iOS app><iOS application><iPhone><iPhone App><iPhone Application><improved><insight><intervention therapy><life-time risk><lifetime risk><mobile assessment><mobile based assessment><mobile device><mobile phone app><morbus Down><neurofilament><older adult><older adulthood><open source><p-tau><p-τ><personnel><phospho-tau><phospho-τ><phosphorylated tau><pilot test><post-translational modification of tau><posttranslational modification of tau><prevent><preventing><primary degenerative dementia><pseudohypertrophic progressive muscular dystrophy><rate of change><research study><senile dementia of the Alzheimer type><sleep pattern><smart phone><smart phone based assessment><smartphone><smartphone application><smartphone based app><smartphone based application><smartphone based assessment><social role><stressor><synuclein><tau phosphorylation><tau posttranslational modification><tau-1><tech development><technology development><trisomy 21 syndrome><validations><τ phosphorylation>